Radioligand therapy with 177 Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use

Nuclear Medicine and Biology

Volumn 43, Issue 12, 2016, Pages 835-

  Ahmadzadehfar, Hojjat ^a   Essler, Markus ^a   Schäfers, Michael ^b   Rahbar, Kambiz ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LUTETIUM 177; PSMA 617 LU 177; UNCLASSIFIED DRUG; 177LU-PSMA-617; DIPEPTIDE; SINGLE HETEROCYCLIC RINGS;

CANCER PATIENT; HUMAN; INDIA; LETTER; METASTATIC PROSTATE CANCER; PERSONAL EXPERIENCE; PROSTATE CANCER; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); MALE; METABOLISM; PROSTATE TUMOR; SECONDARY;

CLINICAL TRIALS AS TOPIC; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84995511042     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2016.08.003     Document Type: Letter

References (5)

1. [1] Das, T, Guleria, M, Parab, A, Kale, C, Shah, H, Sarma, HD, et al. Clinical translation of (177)Lu-labeled PSMA-617: initial experience in prostate cancer patients. Nucl Med Biol 43 (2016), 296–302.
2. [2] Ahmadzadehfar, H, Rahbar, K, Kurpig, S, Bogemann, M, Claesener, M, Eppard, E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res, 5, 2015, 114.
3. [3] Ahmadzadehfar, H, Eppard, E, Kurpig, S, Fimmers, R, Yordanova, A, Schlenkhoff, CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 7 (2016), 12477–12488.
4. [4] Rahbar, K, Bode, A, Weckesser, M, Avramovic, N, Claesener, M, Stegger, L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med 41 (2016), 522–528.
5. [5] Rahbar, K, Schmidt, M, Heinzel, A, Eppard, E, Bode, A, Yordanova, A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med, 2016 Apr 7. pii: jnumed.116.173757. [Epub ahead of print].